Anti-metastatic Profiles of Boesenbergia pandurata towards MCF-7/HER2 Cells by Fadliyah, Hilyatul et al.
68
Fadliyah, et al, 2018
Indones. J. Cancer Chemoprevent., 9(2), 68-77
Anti-metastatic Profiles of Boesenbergia pandurata 
towards MCF-7/HER2 Cells
Hilyatul Fadliyah1, Nindya Budiana Putri1, Ziana Walidah1, Ika Putri Nurhayati2, 
Muthi’ Ikawati1, 3, Edy Meiyanto1, 3,*
1Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
2Department of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Indonesia
3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia
Abstract
  
	 The	development	of	breast	cancer	at	an	advanced	stage	is	signed	with	metastatic	
phenomenon,	triggering	the	high	mortality,	mainly	for	Human	Epidermal	Growth	Factor	
Receptor	(HER)2	positive	cancers.	Boesenbergia	pandurata	is	well	known	as	medicinal	
plant	 possessing	 anticancer	 potential	 due	 to	 the	 cytototoxic	 and	 antimetastatic	
characteristic	 of	 its	 active	 compound.	 The	 aim	 of	 this	 study	 is	 to	 observe	 the	
inhibitory	 effect	 of	 Boesenbergia	 pandurata	 ethanolic	 extract	 (BPEE)	 in	 combination	
with	 doxorubicin	 on	migration	 of	 MCF-7/HER2	 cells.	 The	 BPEE	was	 prepared	 by	 96%	
ethanol	maceration.	Under	MTT	assay,	BPEE	decreased	the	cells	viability	with	IC50	value	
of	 23±3.9	 μg/mL.	 Lamellipodia	 and	wound	 healing	 assay	 analysis	 showed	 that	 5	 μg/
mL	 BPPE	 and	 its	 combination	with	 10	 nM	 doxorubicin	 inhibited	 cells	migration	 after	
48	hours	observation,	while	gelatin	zymography	analysis	showed	that	this	combination	
did	not	affect	the	expression	of	Matrix	Metalloproteinase	(MMP)2	and	MMP9,	but	single	
treatment	of	5	μg/mL	BPEE	caused	lower	expression	of	both	MMPs.	The	combination	of	
5	μg/mL	BPPE	and	10	nM	doxorubicin	inhibited	the	cells	migration	but	not	affect	to	the	
cells	viability.	Thus,	BPEE	is	potential	to	be	developed	as	an	antimetastatic	agent.	The	
mechanism	underlying	the	migratory	inhibition	effect	needs	to	be	explored	further.
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INTRODUCTION
 As many as 90% of breast cancer mortality is 
caused by metastatic phenomena (Lu, et al., 2013a). 
Approximately 20-30% metastatic breast cancer 
cases are caused by over-expression of Human 
Epidermal Growth Factor Receptor (HER)2 (Engel & 
Kaklamani, 2007) acting through motility induction 
and cell invasion along with transforming growth 
factor (TGF)-β1 and TGF-β3 (Seton-Rogers, 2004). 
Unfortunately, in some countries, such as Indonesia, 
detection of breast cancer is just revealed after 
being at metastasis stage (Indonesian Ministry of 
Health, 2015). In fact, breast cancer can metastasize 
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to the other tissues/organs such as bone, brain and 
liver (Chiang & Massagué, 2008). The complexity 
of the disease due to metastasis is still a challenge 
for the development of cancer drugs focusing on 
antimetastatic activity.
 Doxorubicin is known to be the first-line therapy 
for treatment of metastatic breast cancer (Ansari, et 
al., 2007). However, recent studies suggest that the 
use of doxorubicin precisely triggers cancerous cell 
metastasis through epithelial-mesenchymal transition 
(EMT) induction (Bandyopadhyay, et al., 2010), 
and lamellipodia formation as the initial process of 
metastatic cells (Putri, et al., 2011). Alternatively, 
the combination therapy has been developed, such 
as doxorubicin with cyclophosphamide (Swenson, et 
al., 2003; Batist, et al., 2006); and trastuzumab with 
HER2 activated heregulin (Menendez, et al., 2006). 
 Treatment of metastatic cancer requiring 
combination therapy indicates that the cancer at this 
stage is harmful. However, the use of a combination 
of more than one type of chemotherapeutic 
agent rises harmful side effects, including blood 
disorders, nervous system, reproductive system, 
memory system, until damage to the heart, lungs, 
liver, kidneys and other vital organs permanently 
(American Society of Clinical Oncology (ASCO), 
2014). Therefore, the exploration of antimetastasis 
activity from natural plants is still important as an 
effort to look for the combination therapy in order to 
reduce the side effects of chemotherapeutic agents.
 Boesenbergia pandurata is one of the natural 
plants that has been widely studied in terms of the 
anticancer activity. This plant has been reported 
to have phytochemical properties of more than 51 
flavonoid compounds (Chahyadi, et al., 2014) that 
potentially inhibit the growth of various cancer cells, 
including MCF-7 breast cancer cells (Kirana, et al., 
2007). The potency of Boesenbergia pandurata as 
an antimetastatic agent is also found in some cell 
models, one of which is human umbilical vein 
endothelial cells (HUVEC) (Lai, et al., 2015). 
 As mentioned above, HER2 expression 
contribute to the high incidence of metastaic breast 
cancer. However, there have no specific study related 
to antimetastasis activity of Boesenbergia pandurata 
in breast cancer cells over HER2 expression (MCF-7/
HER2). Thus, this study aims to explore the potential 
of Boesenbergia pandurata ethanolic extract 
(BPEE) and its combination with doxorubicin as an 
antimetastasis agent in MCF-7/HER2 breast cancer 
cells.
MATERIALS AND METHODS
Extract Preparation and Thin Layer 
Chromatography
 Rhizome simplicia of Boesenbergia pandurata 
collected from Bina Agro Mandiri Inc. were 
determined at Biological Pharmacy Laboratory, 
Universitas Gadjah Mada. Then it was macerated 
and remacerated with 96% ethanol (1:10) for 5 
days. The filtrate was dried using rotary evaporator 
at 40ºC resulting viscous extract.
 The viscous extract obtained was then 
identified using a thin layer chromatography (TLC) 
method. A total of approximately 10 mg of viscous 
extract dissolved in 0.5 mL of 96% ethanol. The 
mobile phase used is n-hexane : ethyl acetate (4:1 
v/v). 
 The chromatogram profile will be observed 
in the form of color spots appearing under 254 nm 
UV light, then compared with reference of BPEE 
in Indonesian Herbs Pharmacopoeia (First Edition, 
2009) which uses the same mobile phase and 
detection method. 
Cell preparation
 MCF-7/HER2 breast cancer cells were 
obtained from Prof. Masashi Kawaichi (Nara 
Institute of Science and Technology, NAIST, Japan). 
The cells were maintained in Dulbecco’s Modifies 
Eagles medium (DMEM) high glucose (Sigma, Sant 
Louis, USA) with 10% Fetal Bovine Serum (FBS) 
(Sigma), HEPES, sodium bicarbonate, 1500 U/mL 
of Penicilin - 1500 μg/mL of Streptomycin and 0.5 
μg/mL Fungizone (Gibco, New York, USA).
70
Fadliyah, et al, 2018
Indones. J. Cancer Chemoprevent., 9(2), 68-77
Cytotoxic Test
 Cytotoxic test was carried out by MTT assay 
adopted from Mosmann, 1983. Briefly, MCF-7/
HER2 cells were seeded in 96-well plate with 
2.5x103 cells/well and were incubated for 24 hours. 
After incubation, cells were treated with BPEE in 
increasing concentration of 5, 10, 20, 40 and 50 µg/
mL for 24 hours. Media were removed and washed 
with 100 µL phosphate buffered saline/PBS (Sigma). 
MTT reagent was added with the final concentration 
of 5 mg/mL to each wells then incubated in 37oC for 
4 hours then added with sodium dodesyl sulphate 
10% HCl 0.01 N. After thatincubate over night. The 
absorbance was determined with enzyme-linked 
immunosorbent assay (ELISA) reader at λ 595 nm 
(Biorad). 
Lamellipodia Observation
 Cells were grown with a density of 7x104 cells 
/ wells on 6 well plates. Cells were incubated for 24 
hours at 37°C. Cells were added with BPEE with 
the exception of untreated cell was added only the 
culture medium. Observation of lamellipodia’s cell 
formation performed at timepoint 0 and 24 hour 
using inverted microscope at 100x magnification. 
Scratch wound healing assay
 MCF-7/HER2 cells with concentration of 
8.5 x 104 cells/well were seeded in 24-well plate. 
Cells were incubated for 24 hours. Media were 
removed and washed with PBS (Sigma). Media 
with 0.5% FBS were added and incubated for 24 
hours. Each well was scratched vertically by using 
yellow tip and treated with BPEE. The closures of 
cell migration were observed at 0, 24 and 48 hours 
after the treatment under an inverted microscope 
and captured with a digital camera. 
Gelatin Zymography
 The previously planted cells (3x105 cells/
wells) were incubated with BPEE for 24 hours, 
washed with cold PBS and added with 400 μL /
well cold lysis buffer. The lysate was centrifuged 
at 14,000 rpm for 10 min at 4oC. The calculation 
of protein content was conducted using Bradford 
assay method. 
 Stacking and separating gel were prepared 
and incorporated into electrophoresis chamber. 
Approximately lysate of 5-7 μL and prestained 
markers were inserted into the gel wells. 
Electrophoresis was carried out with a condition of 
120 V, 80 mA for 110 min. The electrophoresis gel 
was immersed in 0.05% brilliant blue coomassie 
dye solution for 30 minutes to form a transparent 
band with a dark blue background.
Data Analysis
 Absorbance data was obtained from 
cytotoxicity  assay  then  converted  to  a percent 
of cell viability. IC50 value calculation is performed 
by the linear regression method. Lamellipodia 
observation analysis was done qualitatively  through 
cell  photos  by magnifying  certain spots to observe 
the lamellipodia formed. To make the display 
clearer, photo contrast was made in grayscales 
mode. Scratch analysis was done by measuring 
the migration distance using ImageJ software by 
comparing the distance between the untreated and 
treated cells. Using the  same  software,  gelatin 
zymograph  method was analyzed by comparing the 
band intensity due to the treatment and the untreated 
one.
RESULTS
Characterization of BPEE content using TLC
 Characterization of the content was performed 
using TLC  and compared with the relevant official 
reference according to the Indonesian’ Herbs 
Pharmacopoeia (First Edition, 2009). The BPEE 
chromatogram profile can be seen in Figure 1. 
 The observed results showed that the spots 
arising from the test chromatogram were similar 
in profile with reference chromatogram mentioned 
above. The similarity of profiles between test and 
reference chromatogram was indicated by the 
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Cytotoxic Activity of BPEE Against MCF-7 /
HER2 Cells 
 In addition to know the cytotoxicity of BPEE 
against MCF-7 / HER2 breast cancer cells, cytotoxic 
tests were performed to determine the concentration 
that can be used for observation of the formation 
of lamellipodia, scratch wound healing assay and 
gelatin zymography. The BPEE cytotoxic profile of 
MCF-7 / HER2 cells is shown in Figure 2.
 Based on the results obtained, BPEE inhibited 
the growth of MCF-7/HER2 cells in a dose 
dependent manner. BPEE treatment with higher 
concentration leads to lower cell viability. The 
linear relationship between the concentration and 
cells viability is indicated by the regression value 
that meets the 95% confidence level requirement for 
n=5. The IC50 value of BPEE treatment on MCF-7/
HER2 cells was 23 μg/mL.
The Effect of BPEE Towards the Lamellipodia 
Formation Activity of MCF-7 /HER2 Cells 
 The formation of lamellipodia is an early stage of 
the metastasis process. Observation of lamellipodia 
formation was conducted by observing microscopic 
cell morphology at 24 hours after treatment. The 
concentration of BPEE used in this observation is 
5 μg/mL. In addition, a combination treatment of 
BPEE 5 μg/mL and doxorubicin 10 nM, for further 
mentioned as combination, was performed. In 
general, observation at 24 hours (Figure 3) showed 
the formation of lamellipodia occurring at all 
treatments. However, single treatment of BPEE and 
its combination with doxorubicin 10 nM showed 
less lamellipodia formation than control and single 
treatment of doxorubicin. In other words, BPEE 
treatment and its combination with doxorubicin 
10 nM have the ability to inhibit the formation of 
lamellipodia.
The Effect of BPEE Towards Migration Activity 
of MCF-7/HER2 Cells 
 Another metastasis marker phenomenon is the 
ability of cells to migrate. Observation of MCF-7/
Figure 1. BPEE’s chromatogram profile. The	chroma-
togram	 profile	 was	 obtained	 with	 TLC	 method.	
Silica	 gel	 60	 F	 254	 was	 used	 as	 the	 stationary	
phase.	 Elution	 was	 performed	 using	 n-hexane	 :	
ethyl	acetate	(4:	1	v	/	v)	as	the	mobile	phase.	i:	
Detection	was	carried	out	under	254	nm	UV	light;	
ii:	 chromatogram	 profile	 reference	 of	 BPEE	 ex-
tract;	iii:	pinostrobin	compound	as	a	comparison.
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number of spots. Although not all of the patches on 
the test chromatogram exhibited a position similar 
to that of the reference chromatogram, there was 
a similar position between the chromatogram and 
the reference chromatogram sequentially in spots 
1 to 2 (hRF 19), 2 spots with 3 (hRF 30), 5 spots 
with 5 (hRF 64), and spots 6 with 7 (hRF 87). 
With the similarity of the profiles, BPEE used in 
this study met the official reference standard. 
Interestingly, in the fifth spots both the test and 
reference chromatograms have similarities with 
spot of pinostrobin, a flavonoid, as compounds used 
by reference. This finding reinforces that the sample 
used is a Boesenbergia pandurata containing 
flavonoid compounds.
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Figure 2. Effects of BPEE treatment on cytotoxic tests. Cells	 were	 seeded	 in	 96	 well	 plates	 with	 a	 den-
sity	 of	 2.5x103	 cells/wells	 and	 incubated	 for	 24	 hours.	 Cells	 were	 starved	 and	 treated	 with	 BPEE	 in	
various	 concentrations	 of	 5,	 10,	 20,	 40	 and	 50	 μg/mL	 for	 24	 hours.	 A:	 Cell	 morphology	 after	 treat-
ment	 with	 0,	 5,	 20,	 and	 50	 μg/mL	 BPEE	 for	 24	 hours;	 B:	 Quantification	 of	 cell	 viability	 after	 treat-
ment	 with	 5,	 10,	 20,	 40	 and	 50	 μg/mL	 for	 24	 hours,	 as	measured	 using	 MTT	method.	 The	 graph	 above	 is	
the	 percentage	 of	 cell	 viability	 of	 three	 independent	 experiment	 values	 with	 95%	 confidence	 level.
HER2 cell migration activity due to treatments 
of BPEE, doxorubicin, and its combination was 
performed with scratch wound healing assay using 
starvation media. 
 
0 
24 
Untreated Dox 10 nM BPEE 5 μg/mL Combination 
Time point (hour) 
Figure 3. Effect of treatments on lamellipodia formation activity. Cells	 with	 a	 density	 of	 7.5	 x	 104	 cells/
well	 were	 seeded	 on	 24	 well	 plates.	 The	 observations	 were	 performed	 using	 inverted	 microscope	 at	
100x	 magnification	 after	 24	 hours	 treatment	 incubation.	 The	 red	 arrow	 shows	 the	 formed	 lamellipodia.	
 The result of scratch wound healing assay and 
quantification of the area of closure due to migration 
by MCF-7/HER2 is shown in Figure 4. 
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Figure 4. Inhibitory effect of migration. Cells with a 
density of 7.5x104 cells/well were seeded on 24 
well plates. A:	Cell	morphology	after	scratch	wound	
healing	assay	and	treated	with	5	μg/mL	BPEE	10nM	
Doxorubicin	and	a	combination	of	both.	Observa-
tions	were	performed	at	0,	24,	and	48	hours	after	
treatment	under	an	inverted	microscope	with	100x	
magnification.	The	dashed	lines	indicate	the	bor-
der	of	the	scatch;	B:	Percentages	of	MCF-7/HER2	
cell	closure	at	24	and	48	hours	were	obtained	from	
average	%	closure	of	three	observed	areas	in	one	
well	 at	 the	 same	 time.	The	 area	was	 quantified	
using	ImageJ®	software	and	calculated.	SD	values	
were	obtained	from	three	different	observations.
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 The quantification result is done by  making 
a  line  adjusting the cell boundary using unshaped 
tools  instead  of  straight lines, so that the area of 
the cavity also included in the  calculation.
 At the 24th hour observation, a single 
treatment of BPEE decreased the % closure when 
compared with untreated cell and single treatment 
of doxorubicin. From the quantification chart it 
can be seen that the lowest % closure occurred in 
the treatment of a combination  of  BPEE  with 
doxorubicin 10 nM, either at the time of 24 or 48 
hours of  observation.  This  indicated  that  the 
combination treatment of both agents provides 
better anti-migration  effects, yet  statistically 
insignificant.
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Figure 5. Inhibitory effect of MMP-2 and MMP-9 expression. Cells	with	a	density	of	7.5	x	104	cells/well	were	seeded	
on	24	well	plates.	The	starvation	medium	is	taken	as	a	lysate	after	24	hours	of	incubation	as	the	sample	used.	
A:	Profiles	of	MMP-2	and	MMP-9	expression	bands;	B:	Quantification	of	transparent	band	intensity	of	MMP-2	and	
MMP-9	by	three	times	of	analysis.	Observation	of	MMP-2	and	MMP-9	expression	was	done	by	gelatin	zemography	
according	to	the	research	method.	The	results	analysis	was	performed	using	ImageJ®	software	to	measure	the	
intensity	of	the	gelatine	degradation	bands	by	MMP-2	and	MMP-9	on	the	gel	with	three	times	of	calculation.
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The Effect of BPEE Towards MMP-2 and MMP-
9 Expression of MCF-7/HER2
 BPPE was proven to inhibit the expression 
of matrix metalloproteinase (MMP)-2 and MMP-9 
proteins. The method used for MMP-2 and MMP-9 
expression test on MCF-7/HER2 cells in this study 
was gelatin zymography.
 Based on this result, it can be seen that there 
was no huge different of  the decrease of MMP-
9 expression between BPEE single treatment and 
combination treatment (Figure 5). While BPEE 
treatment was more able to decrease MMP-2 
expression compared with other treatments. The 
combination of BPEE-doxorubicin 10 nM was only 
able to decrease MMP-9 expression when compared 
with other treatments. This is  contrary to the 
migration observations, single treatment of BPEE 
has a better migration inhibitory effect in terms of 
inhibition of MMP-2 expression and MMP-9 than 
combination treatment.
DISCUSSION
 Boesenbegia pandurata in the form of extracts 
with various solvents have been shown to have 
anticancer activity in many experimental models of 
cancer cells, both in vitro and in vivo. The anticancer 
potential can be seen through the cytotoxic profile 
obtained. In this study it was proven that BPEE has 
anticancer potential in MCF-7/HER2 cells with 
IC50 values lower than 100 μg/mL as described by 
Prayong, et al. (2008). Cancer mechanism itself 
can occur differently. Of the ten characteristics 
of cancer cells (Hanahan & Weinberg, 2011), the 
phenomenon of metastasis is often targeted as a 
target for the development of cancer drugs. This 
is due to many cases of cancer, including breast 
cancer.
 A study related to the effect of Boesenbergia 
pandurata as antimetastasis agent has been 
done, but no metastatic breast cancer-related 
studies have been found. This study positioned 
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itself to complement by focusing on the effect of 
Boesenbergia pandurata towards breast cancer cells 
with overexpression of HER2. The presence of 
excessive HER2 expression in the cell model used 
indicates the metastatic characteristics of the cancer 
cells. 
 The metastasis profiles in this study covered 
the formation of lamellipodia, % of closure due 
to scratch wound healing assay, and % band 
intensity due to gelatin degradation by MMP-2 and 
MMP-9. In this study, we also enclosed the single 
treatment of doxorubicin that proven to trigger 
the formation of lamellipodia (Putri, et al., 2011) 
with 10 nM concentration without causing death 
cells (Amalina, et al., 2017). Additionally, the 
combination of BPEE with doxorubicin was added 
to their respective concentration in order to know the 
potential of BPEE as MCF-7/HER2 breast cancer 
co-chemotherapeutic agent. From the results of the 
research, it was found that BPEE and its combination 
with doxorubicin 10 nM could inhibit the formation 
of lamellipodia. Lamellipodia observation involves 
a narrower field of view, meaning the observations 
focused on the cells one by one. Based on the 
inhibitory effect of lamellipodia formation by BPEE 
and its combination with chemotherapeutic agents, 
it shows the potential of BPEE to be developed as 
an antimetastasis agent. 
 Beside that, the closure of the scratch wound 
healing assay represents the movement of the 
cell with a wider field of view, it can be seen the 
phenomenon of migration of the observed cells as a 
whole. This observation also included doxorubicin 
treatment of 10 nM, whereby it has been known 
to induce metastasis via induction of epithelial-
mesencymal transition (EMT) (Bandyopadhyay, et 
al., 2010). Epithelial cells experience a reduction in 
polarity and adhesion, thus causing epithelial cells 
to have characteristics such as mesenchymal cells 
capable of migrating and invading (Kalluri and 
Weinberg, 2009). 
 Furthermore, there is also included a 
combination treatment of both to determine 
the potential of BPEE when combined with 
chemotherapeutic agents in inhibition of MCF-7/
HER2 cell migration. BPEE treatment was able 
to decrease the percentage of closure at 24 hours 
observation, and the combination of BPEE with 
doxorubicin 10 nM was known to decrease the 
percentage of closure compared to untreated cell and 
single treatment of doxorubicin, either at 24 hours 
or 48 hours. The decrease  effect  of  %  closure 
becomes  important  information  that  can be used 
as a basis for BPEE development as a combination 
of cancer chemotherapy or co-chemotherapy 
agents. 
 The molecular review of the invasion process 
was conducted by observing the inhibition of MMP-
2 and MMP-9 expression. As far as we explored, 
there has not been found a study of doxorubicin’s 
effect toward the expression of MMP-2 and MMP-9. 
So the doxorubicin treatment in this case is an initial 
investigation to assess the effect of doxorubicin with 
MMP-2 and MMP-9, since migration and invasion 
mechanisms are not the same although related. 
This stody showed that all treatments tending to 
decrease the expression of MMP-2 and MMP-9, 
except untreated cells. Although one treatment with 
other treatments showed no significant difference, 
a single BPEE treatment was more able to decrease 
the expression of both MMP. Therefore it can be 
said that BPEE has the potential to be developed 
as an antimetastasis agent through a decrease in the 
expression of MMP-2 and MMP-9 in breast cancer 
cells overexpression of HER2. Nevertheless, the 
refinement of this study is very necessary to do. 
 This study shows that BPEE has the ability 
to inhibit breast cancer cell metastasis over 
HER2 expression. To accomplish this research, 
a metastatic study should be conducted through 
another approach with regard to metastatic cascades, 
such as intravasation, circulation, extravasation and 
angiogenesis both in vitro and/or in vivo. Metastatic 
studies through migratory inhibition and invasion 
approaches can also be performed with other 
methods such as transmembrane assay (Boyden 
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chamber assay), microfluidic chamber assay, and 
cell exclusion zone assay (Hulkower, et al., 2011). 
Molecular studies of MMP-2 expression, MMP-
9 and other factors affecting both proteins can be 
explored more deeply by performing other methods 
such as Western blot. 
CONCLUSION
 Overall, the results of this study indicate that 
BPEE has potential as an antimetastasis agent in 
MCF-7/HER2 cells, in view of the tendency to 
inhibit lamellipodia formation, cell migration and 
MMP-2 and MMP-9 activity.
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